NCT02954263

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-1439 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Theravance Biopharma · Industry
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects

Conditions

• Healthy Adults, Elderly Subjects

Interventions

Type	Name	Description
DRUG	TD-1439
DRUG	Placebo

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-02-01
• Completion: 2017-04-01
• First posted: 2016-11-03
• Last updated: 2021-01-20

Locations

1 site across 1 country: United States